Health Canada has approved lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) radioligand therapy (Pluvicto, Novartis) for the treatment of patients with metastatic prostate cancer.
The radiopharmaceutical drug is indicated for adult patients with PSMA-positive metastatic castration-resistant prostate cancer who have previously received other anticancer therapies, such as androgen receptor therapy or taxane-based chemotherapy.
Prostate cancer is the most diagnosed cancer among Canadian men and is the third leading cause of cancer-related death in men in Canada.
Pluvicto was approved by the U.S. Food and Drug Administration in March.
